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Simple Summary: Chemotherapy of solid tumors has made very slow progress over many decades.
A major problem has been that solid tumors very often contain non-dividing cells due to lack of
oxygen deep in the tumor and these non-dividing cells resist most currently-used chemotherapy
which usually only targets dividing cells. The present review demonstrates how a unique imaging
system, FUCCI, which color codes cells depending on whether they are in a dividing or non-dividing
phase, is being used to design very novel therapy that targets non-dividing cancer cells which can
greatly improve the efficacy of cancer chemotherapy.
Abstract: Progress in chemotherapy of solid cancer has been tragically slow due, in large part,
to the chemoresistance of quiescent cancer cells in tumors. The fluorescence ubiquitination cell-cycle
indicator (FUCCI) was developed in 2008 by Miyawaki et al., which color-codes the phases of the cell
cycle in real-time. FUCCI utilizes genes linked to different color fluorescent reporters that are only
expressed in specific phases of the cell cycle and can, thereby, image the phases of the cell cycle in
real-time. Intravital real-time FUCCI imaging within tumors has demonstrated that an established
tumor comprises a majority of quiescent cancer cells and a minor population of cycling cancer cells
located at the tumor surface or in proximity to tumor blood vessels. In contrast to most cycling
cancer cells, quiescent cancer cells are resistant to cytotoxic chemotherapy, most of which target cells
in S/G2/M phases. The quiescent cancer cells can re-enter the cell cycle after surviving treatment,
which suggests the reason why most cytotoxic chemotherapy is often ineffective for solid cancers.
Thus, quiescent cancer cells are a major impediment to effective cancer therapy. FUCCI imaging
can be used to effectively target quiescent cancer cells within tumors. For example, we review how
FUCCI imaging can help to identify cell-cycle-specific therapeutics that comprise decoy of quiescent
cancer cells from G1 phase to cycling phases, trapping the cancer cells in S/G2 phase where cancer
cells are mostly sensitive to cytotoxic chemotherapy and eradicating the cancer cells with cytotoxic
chemotherapy most active against S/G2 phase cells. FUCCI can readily image cell-cycle dynamics at
the single cell level in real-time in vitro and in vivo. Therefore, visualizing cell cycle dynamics within
tumors with FUCCI can provide a guide for many strategies to improve cell-cycle targeting therapy
for solid cancers.
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1. Introduction
In normal cells, the cell cycle is strictly regulated and organized and comprises G1-S-G2-M
phases with an inactive/quiescent G0 state. The cell cycle of cancer cells also comprises four distinct
phases of the cell cycle [1], but the regulation of the various phases may be altered [2–6]. It is
imperative to identify more effective cell-cycle-phase-specific therapeutic agents, especially to target
quiescent cells within tumors, which may confer chemoresistance due to their quiescence (Figure 1).
The fluorescence ubiquitination cell-cycle indicator (FUCCI) was developed in 2008, which can visualize
and identify the cell-cycle phase of cells in real-time [7] (Figure 2). FUCCI utilizes genes linked to
different-color fluorescent reporters that are only expressed in specific phases of the cell cycle. FUCCI
enables the visualization of the cell cycle of any cell type in real-time. For example, FUCCI imaging
enables visualization of real-time cell cycle changes of individual live cancer cells, including during
chemotherapy. FUCCI real-time imaging of the cell-cycle phases at the single-cell level in solid tumors
in live mice has shown that the vast majority of cancer cells in established experimental tumors are
not cycling and remain in the G0/G1 phase [8,9]. FUCCI imaging showed that cycling cancer cells in
the S/G2/M phases are located only near the surface of the tumor or near tumor blood vessels [7–9].
Cancer cells in the G0/G1 phase can be the vast majority of cells in solid tumors, which makes cytotoxic
chemotherapy of solid tumors often problematic [8,9]. The resistance of quiescent cancer cells to
conventional therapy is currently a recalcitrant clinical problem that results in tumor recurrence after
chemotherapy and poor prognosis in cancer patients [10–16]. The present review focuses on the
ability of FUCCI to image cell-cycle dynamics within tumors in order to develop a guide for improved
targeted therapy of solid tumors, especially against quiescent cancer cells.
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Figure  1.  Scheme  of  cell‐cycle phases where  therapeutic  agents  are most  effective, which  can  be 
imaged with the fluorescence ubiquitination cell‐cycle indicator (FUCCI). 
i re 1. c e e of cell-cycle phases where therapeutic agents are most effective, which can be imaged
with the fluorescence ubiquitination cell-cycle indicator (FUCCI).
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2. FUCCI Images Cell‐Cycle Dynamics of Cancer Cells in Real‐Time 
To develop cell‐cycle targeted cancer therapy, it is critical to monitor cell‐cycle phases in real‐
time  for appropriate targeting of  therapeutics to specific phases of  the cell cycle. As noted above, 
Sakaue‐Sawano  et  al.  [7] developed  the  FUCCI  system for  visualizing  cell‐cycle  dynamics  of 
individual cells  in real‐time by color‐coded fluorescence  imaging (Figure 2). FUCCI utilizes genes 
linked to different color fluorescent reporters, such as Cdt1 and Geminin, that only appear in specific
phases of the cell cycle. The original FUCCI comprised two plasmids: Cdt1‐mKO2 (orange fluorescent 
protein), expressed in G1 phase and Geminin linked to mAG (green fluorescent protein) expressed in 
late‐S‐phase. In early‐S phase where the expression of Cdt1‐mKO2 is the same as that of Geminin‐
mAG, the cells appear yellow. Therefore, FUCCI‐red indicates the quiescent G1 phase, FUCCI‐green 
indicates  the  proliferating late‐S/G2/M  phase,  and  FUCCI‐yellow  indicates  the  early‐S  phase  [7]
(Figure  2).  Sakaue‐Sawano  et  al.  [17]  also have  developed a  new  FUCCI with  improved  color 
specificity  over  the  original  FUCCI,  termed  FUCCI2.  Sakaue‐Sawano  et  al.  [18] subsequently 
developed FUCCI (CA), which produces a sharp triple‐color distinct separation of G1, S, and G2, and 
can distinguish  the  transition  from G1 phase  to S phase  (Figure 2). The original FUCCI could not 
distinguish between the G0 and G1 phases. Therefore, Oki et al. [19] modified FUCCI, which enabled 
a distinction between G0 and G1. Bajar et al. [20] created FUCCI4, which distinctly images four cell‐
cycle phases  and  enables specific imaging of S phase, with mTurquoise  linked with  an S‐phase‐
specific protein, stem‐loop binding protein (SLBP), andM phase, with mMaroon linked to histone H‐
1.0 for imaging chromatin condensation during mitosis [20] (Figure 2). FUCCI4 also visualizes the 





Figure 2. Comparison of the different FUCCI systems.
2. FUCCI Images Cell-Cycle Dynamics of Cancer Cells in Real-Time
T develop cell-cycle targeted cancer therapy, t is critical to monitor c ll-cycle ph ses in
real-time for appropriate targ ting of therapeutics to specific phases of th cell cycle. As noted
abo e, S kaue-Sawano et al. [7] developed the FUCCI system for visualizing cell-cycle dynamics of
i dividual c lls in real-time by color-c d d fl orescence imaging (Figure 2). FUCCI utilizes genes
linked to different color flu escent reporters, such as Cdt1 and Geminin, that only appear in specific
hases of the cell cycle. The origi al FUCCI comprised two plasmids: Cdt1-mKO2 (orange fluoresce t
protein), expressed in G1 phase and Geminin linked to mAG (green fluor scent pro ein) expr ssed in
late-S-phas . In early-S phase where the xpression of Cdt1-mKO2 is the ame as that of Geminin-mAG,
the ells appear yellow. Therefore, FUCCI-red indicates the qui scent G1 phase, FUCCI-green indicates
the proliferating late-S/G2/M phase, and FUCCI-yellow in icates the early-S p ase [7] (Figure 2).
Sakaue-Sawano et al. [17] also have develop a new FUCCI with improved color specificity ov r the
original FUC I, termed FUCCI2. Sakaue-Sawano et al. [18] subsequently developed FUCCI (CA),
which produces a sh rp triple-color distinct separation of G1, S, and G2, and can disting ish the
transition from G1 phase to S phase (Figure 2). The original FUCCI coul not distinguish between the
G0 and G1 phases. Therefore, Oki et l. [19] modified FUCCI, which enabled a distinction between G0
and G1. Bajar et al. [20] creat d FUCCI4, which distinctly images four cell-cycl phases d enabl s
s ecific imaging of S phase, with mTurquoise linke wit an S-p ase-specific protein, stem-loop
binding protein (SLBP), and M phase, with mMaroon linked to histone H-1.0 for imaging chromatin
condensation during mitosis [20] (Figure 2). FUCCI4 also visualizes the specific cell-cycle phase in
real-time, similar t FUCCI (CA). A problem with the riginal FUCCI was the need to use two eparate
plasmids, which may not be equally expressed, thereby confusing th color specificity of the various
cell-cycle phases. Fa tFUCCI was subsequently developed, which has an all-in-one expression cassette
that has all FUCCI gen s under the control of a single promoter, resulting in their equal expression;
these different FUCCI systems are compared in Figure 2 [21].
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FUCCI Imaging Demonstrates Different Cell-Cycle Dynamics in 2D- and 3D-Cultured Cancer Cells
FUCCI imaging has visualized the difference in cell-cycle dynamics between two-dimensional
(2D) culture, where the majority of cells are in S/G2/M, and three-dimensional (3D) culture, where cells
are mostly in the G1 phase, similar to cancer cells in tumors, as reviewed below [8,9]. This explains,
in part, why cancer cells in 2D culture are usually chemosensitive and cancer cells in 3D and in vivo
are less chemosensitive or chemoresistant (Figure 3). FUCCI imaging can facilitate the discovery
of effective cell-cycle targeting drugs in vitro, especially against quiescent cancer cells, which can
predominate in the 3D culture of cancer cells and in vivo.
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Figure 3. Representative FU CI image of MKN45 cancer cells in 2D and 3D culture and in vivo.
FUCCI cells in 2D in vitro (A). FUCCI cells in 3D sphere culture in vitro (B). FUCCI imaging of cancer
cells in tumors in vivo (C). The cells in G1, early-S, or late-S/G2/M phases appear in red, yellow,
or green, respectively. Note: the preponderance of FUCCI-green proliferating cells in 2D-culture and
the preponderance of FUCCI-red quiescent cells in 3D-culture and in tumors. [22]. Scale bar; 100 µm.
3. Real-time FUCCI Imaging of Cell-Cycle Dynamics of Cancer Cells in Solid Tumors
Intravital in-vivo real-time imaging provides the scene of cancer cells within tumors
(Figure 4) [23–30]. Intravital real-time imaging of orthotopic FUCCI-expressing tumors in the liver of
live mice was performed at various stages of progression. In these studies, a nascent tumor comprised
mostly proliferating cancer cells expressing FUCCI-yellow and FUCCI-green [8,9] (Figure 4). In contrast,
an established larger tumor comprised mostly quiescent cancer cells expressing FUCCI-red. In a
late-stage tumor, proliferating cancer cells were located only at the surface area or adjacent to blood
vessels of tumors (Figure 4) [8,9]. However, it should be noted that same late-stage tumors may have a
large number of proliferative cancer cells. FUCCI imaging demonstrated that the cell-cycle phase of
each cancer cell in a tumor depends, at least in part, on its location within a tumor; proliferating cancer
cells are located near the surface or blood vessels, and quiescent cancer cells are in the central area
of tumors, where they become hypoxic and are starving for nutrition [8,9]. Of course, many factors
determine the drug resistance of cancer cells, but their location within tumors is important since it can
determine access to oxygen and nutrients. Some very well vascularized large tumors may have a greater
fraction of cycling cells. Haass et al. [31] and Goto et al. [32] demonstrated that FUCCI-expressing
cancer cells were arrested in G1 phase during hypoxia and restarted proliferation when oxygen was
supplied. Chittajallu et al. [33] also performed intravital FUCCI imaging, in their case, of HT1080
fibrosarcoma cells in a dorsal skin-fold chamber in nude mice and demonstrated that tumors in the
chamber comprised approximately 60% of cancer cells in G1 phase and approximately 29% of cells
in S/G2/M phases, similar to the results described above. Haass et al. [31] also demonstrated with
FUCCI that quiescent melanoma cells were located far from the tumor vasculature, and proliferating
melanoma cells were located near tumor vessels within FUCCI-expressing melanoma tumors [31].
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FUCCI  imaging  of HeLa  cancer  cells  in  2D  culture demonstrated  that  5‐fluorouracil  (5‐FU) 
arrests cancer cells in late‐S/G2 phases without changing the shape of treated cells, and cisplatinum 
arrests  all  cancer  cells  in  late‐S/G2 phases, which  acquire  a  spindle  shape. Doxorubicin  similarly 
arrests cancer cells in late‐S/G2 phases with a spindle shape. Cancer cells surviving doxorubicin were 
induced  to  undergo  nuclear mis‐segregation  (Figure  5).  FUCCI1  imaging  in  2D  in‐vitro  culture 
demonstrated that chemotherapeutic agents and irradiation arrest some cancer cells in late‐S/G2/M 
phases [8,9,21,23]. FUCCI2 imaging of normal murine mammary gland cells (NMuMG) showed that 
an  intermediate  concentration  of  etoposide  induced  nuclear  mis‐segregation  and  a  high 
concentration of etoposide  induced DNA endoreplication  [17]. Koh et al.  [21] used FastFUCCI  to 
show cell‐cycle dynamics of cancer cells  treated with a  taxane. Haass  [31] also demonstrated  that 
FUCCI‐red‐expressing  melanoma  cells  in  G0/G1  phase  survived  an  MEK  inhibitor  or  a  BRAF 
inhibitor. Melanoma spheroids, which survived MEK inhibitors or BRAF inhibitors, recovered and 
expanded after cessation of treatment, as demonstrated by FUCCI imaging [31]. FUCCI imaging can 
thus  identify  the  cell  cycle  phase  that  drug‐resistant  cancer  cells  arrest  in,  which  can  suggest 
subsequent treatment to kill the resistant cells. 
Figure 4. I travital FU CI imaging of tumors at various stages and depths. (A) Scheme of
intravital imaging of FUCCI cancer c lls in the liver of nude mice with a confocal la er microscope.
(B–D) Representative images of FUCCI-expressing tumors at various stages, at the indicated depth
from the surfac . (E) Represent tive images f 3D rec struction of FUCCI tumors at 7 and 28 days of
growth. The cells in G1, early-S, or late-S/G2/M phases appear red, yellow, or green, respectively [8].
The ability to image the cell cycle of cancer cells within a tumor spati ll and temporally can
enable the discovery f more effective cell-cycle-targeting therapeutics.
4. FUCCI Imaging of Cell-Cycle Phases of Cancer Cells during Chemotherapy and Radiotherapy
In Vitro and In Vivo Identifies Resistant Cells
FUCCI imaging of H La cancer cells in 2D culture demonstrated that 5-fluorouracil (5-FU) arr sts
cancer lls in late-S/G2 phases without ch nging the shape of treated cells, and cisplatinum arrests all
cancer cells in la e-S/G2 phas s, which acquire a spin le shape. Doxorubicin similarly arrests cancer
cells in late-S/G2 phases with a spindle shape. Canc r cells survivi g doxorubicin were induced to
undergo nuclear mis-segreg ti (Figure 5). FUCCI1 imaging in 2D in-vitro culture demonstrated
that chemotherapeutic agents and irradiation arrest some cancer cells in late-S/G2/M phases [8,9,21,23].
FUCCI2 imaging of normal murine mammary gland cells (NMuMG) showed that an intermediate
concentration of etoposide induced nuclear mis-segregation and a high concentration of etoposide
induced DNA endoreplication [17]. Koh et al. [21] used FastFUCCI to show cell-cycle dynamics
of cancer cells treated with a taxane. Haass [31] also demonstrated that FUCCI-red-expressing
melanoma cells in G0/G1 phase survived an MEK inhibitor or a BRAF inhibitor. Melanoma spheroids,
which survived MEK inhibitors or BRAF inhibitors, recovered and expanded after cessation of treatment,
as demonstrated by FUCCI imaging [31]. FUCCI imaging can thus identify the cell cycle phase that
drug-resistant cancer cells arrest in, which can suggest subsequent treatment to kill the resistant cells.
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immunodeficient  zebrafish  that  combination  therapy  of  olaparib,  a  PARP  inhibitor,  and 
temozolomide arrested the rhabdomyosarcoma cells in the G2 phase and induced apoptosis. 
FUCCI imaging showed that X‐irradiated cancer cells were arrested at the G2 checkpoint in vitro 
[35]. Onozato  et  al.  [35]  showed  that  irradiation decreased FUCCI‐green‐expressing proliferative 
cancer cells and increased FUCCI‐red‐expressing quiescent cancer cells in vitro. Bouchard et al. [36] 
also demonstrated  that  there  are more FUCCI‐red‐expressing quiescent  cancer  cells  in  irradiated 
mammary glands than control mammary glands. 
Figure 5. Representative images of responses of F a cells to cy toxic agents. FUCCI HeLa
cancer cells were treated with 5-FU, cisplatinum, and doxorubicin. The cells in G1, early-S, or late-S/G2/M
phases appear red, yellow, or green, respectively [32]. Scale bar; 100 µm.
FUCCI imaging showed that nascent tumors, comprising mostly cycling cancer cells, are sensitive to
chemotherapy. In contrast, quiescent cancer cells within established tumors that survive chemotherapy
will restart cycling and increase after the removal of chemotherapeutic agents (Figure 6) [8,9].
Chittajallu et al. [33] also used FUCCI imaging for the quantitative analysis of cancer drug efficacy,
spatially and temporally, at the single-cell level in tumors of live mice and demonstrated similar results.
Yan et al. [34] demonstrated with FUCCI imaging of rhabdomyosarcoma growing in immunodeficient
zebrafish that combination therapy of laparib, a PARP inhibitor, and temozolomide arrested the










labels  nascent  blood  vessels  with  GFP  within  tumors  [39]  (Figure  7),  was  used  to  visualize 
angiogenesis, along with FUCCI imaging, which demonstrated that cycling cancer cells are located 
near  tumor vessels and quiescent  cancer  cells are  located  far  from  tumor vessels  (Figure 7)  [8,9]. 
FUCCI  imaging  with  GFP‐expressing  tumor  vessels  showed  nascent  tumor  blood  vessels  and 
increased  angiogenesis  occurring  among  the  chemo‐resistant  cancer  cells  within  the  tumor. 
Angiogenesis  increased  within  areas  where  quiescent  resistant  cancer  cells  survived  after 
chemotherapy  (Figure  8)  [40].  This  is  another  reason  why  quiescent  cancer  cells  surviving 
chemotherapy  can  rapidly  restart  cycling  after  cessation  of  chemotherapy  and  become  more 
aggressive. Tumors can vary with regard to their degree of vascularization, which must be taken into 
consideration. Ironically, cancer cells that become resistant to cytotoxic agents not only become much 
more  refractory  to  chemotherapy  but  can  become more  aggressive  and more metastatic  [41,42]. 
FUCCI  imaging  can  provide  a  very  useful  tool  to  discover  drugs  that  can  overcome  the 
chemoresistance of cancer cells. 
Figure 6. Response to cytotoxic chemotherapy of t t different stages, visualized by FUCCI.
Representative images of FUC I-expres i ors treated with cisplatinum. The cells in G0/G1,
early S, r l t S/ 2/M pha es appear red, yell w, or gre n, respectively [8]. Scale bar; 500 µm.
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FUCCI imaging showed that X-irradiated cancer cells were arrested at the G2 checkpoint
in vitro [35]. Onozato et al. [35] showed that irradiation decreased FUCCI-green-expressing proliferative
cancer cells and increased FUCCI-red-expressing quiescent cancer cells in vitro. Bouchard et al. [36]
also demonstrated that there are more FUCCI-red-expressing quiescent cancer cells in irradiated
mammary glands than control mammary glands.
5. FUCCI Imaging Identified Angiogenesis Occurring Among Resistant Cells During
Chemotherapy of Tumors
Angiogenesis and anti-angiogenesis therapeutics are still active areas of cancer biology
research [37,38]. A transgenic nude-mouse model, in which the nestin promoter drives GFP expression
and labels nascent blood vessels with GFP within tumors [39] (Figure 7), was used to visualize
angiogenesis, along with FUCCI imaging, which demonstrated that cycling cancer cells are located
near tumor vessels and quiescent cancer cells are located far from tumor vessels (Figure 7) [8,9].
FUCCI imaging with GFP-expressing tumor vessels showed nascent tumor blood vessels and increased
angiogenesis occurring among the chemo-resistant cancer cells within the tumor. Angiogenesis
increased within areas where quiescent resistant cancer cells survived after chemotherapy (Figure 8) [40].
This is another reason why quiescent cancer cells surviving chemotherapy can rapidly restart cycling
after cessation of chemotherapy and become more aggressive. Tumors can vary with regard to their
degree of vascularization, which must be taken into consideration. Ironically, cancer cells that become
resistant to cytotoxic agents not only become much more refractory to chemotherapy but can become
more aggressive and more metastatic [41,42]. FUCCI imaging can provide a very useful tool to discover
drugs that can overcome the chemoresistance of cancer cells.Cancers 2020, 12, x  8  of  18 
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Cancer  stem cells  (CSCs) have  the ability  to  self‐renew and  initiate  tumors  [43,44]. CSCs are 
resistant  to  cytotoxic agents  since  they have more drug  transporters, are more protective against 
reactive oxygen species (ROS), and proliferate more slowly than non‐CSCs. Previously, before FUCCI 
was developed, it was difficult to monitor the cell‐cycle phase dynamics of CSCs. FUCCI imaging 
showed  that CSCs are quiescent compared with non‐CSCs, even  in  two‐dimensional culture  [45]. 
Spheroid 3D culture is frequently used to grow CSCs. FUCCI imaging demonstrated that spheroids 
derived from CSCs are arrested in the G1 phase for more than 8 days [45]. Using FUCCI real‐time 





Figure 7. Intravital imaging of GFP-expressing tu or blood vessels and FUCCI-expressing cancer
cells in tumors at different stages and at depths within tumors. (A) Representative images of tumor
angiogenesis in nude mice expressing nestin-driven GFP in nascent blood vessels. Cancer cells induce
tumor angiogenesis. Scale bar; 500 µm. (B) Representative images of FUCCI-expressing tumors with
GFP-expressing tumor vessels at the indicated depth from the surface. (C) Representative images of 3D
reconstruction of FUCCI tumors, with visualized tumor vessels at 14 days or 28 days after implantation.
Arrowheads indicate tumor vessels. Arrows show quiescent areas of the tumor. (D) Scheme of FUCCI
cancer cells and tumor vessels [8,22].
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6. Use of FUCCI to Identify and Target Quiescent Cancer Cells In Vitro and In Vivo
Quiescent cancer cells are important therapeutic targets as they can resist most cytotoxic
chemotherapy, then cycle after the cessation of therapy. This section focuses on novel strategies
afforded by FUCCI imaging to identify, decoy, attack, and kill quiescent cancer cells in tumors, as well
as in vitro.
6.1. FUCCI Imaging Can Identify and Target Quiescent Cancer Stem Cells
Cancer stem cells (CSCs) have the ability to self-renew and initiate tumors [43,44]. CSCs are
resistant to cytotoxic agents since they have more drug transporters, are more protective against
reactive oxygen species (ROS), and proliferate more slowly than non-CSCs. Previously, before FUCCI
was developed, it was difficult to monitor the cell-cycle phase dynamics of CSCs. FUCCI imaging
showed that CSCs are quiescent compared with non-CSCs, even in two-dimensional culture [45].
Spheroid 3D culture is frequently used to grow CSCs. FUCCI imaging demonstrated that spheroids
derived from CSCs are arrested in the G1 phase for more than 8 days [45]. Using FUCCI real-time
imaging, CSCs were imaged to begin to divide when fetal bovine serum (FBS) was added to the
culture medium [45]. Haass et al. [31] also demonstrated that FUCCI-expressing melanoma spheroids
comprised FUCCI-red quiescent cells. In contrast, FUCCI melanoma spheroids started proliferation
and cell division when FBS was added. FUCCI imaging can facilitate the discovery of effective cell-cycle
targeting drugs specific for quiescent CSCs, as discussed below.
6.2. Decoy of Quiescent Cancer Stem Cells to Commence Cycling with a Tumor-Targeting Adenovirus,
Demonstrated by FUCCI Imaging
FUCCI imaging showed that quiescent CSCs were resistant to conventional chemotherapy,
as mentioned above [45]. Therefore, a cell-cycle decoy of CSCs to cycle would be a promising
therapeutic option. Using a genetically-engineered telomerase-specific tumor-targeting adenovirus,
OBP-301 [46,47], FUCCI imaging showed that the adenovirus decoyed and trapped quiescent CSCs
from the G1 phase into S/G2 phases, where the decoyed CSCs became sensitive to chemotherapy
in vitro and in vivo (Figure 8) [45].
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Figure 8. Cytotoxic chemother induces tumor angiogenesis. (A) Representative images of
FUCCI-expressing tumors with visualized GFP-expressing tumor vessels before chemotherapy.
(B) Representative images of FUCCI-expressing tumors with visualized GFP-expressing tumor vessels
after chemotherapy. Elongated green structures are GFP-expressing nascent tumor vessels formed in
transgenic mice expressing nestin-driven GFP [40,48]. Scale bar; 500 µm.
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6.3. Tumor-Targeting Salmonella Typhimurium Decoys Quiescent Cancer Cells in Tumors to Cycle and Become
Chemosensitive, Shown by FUCCI Imaging
FUCCI imaging showed that tumor-targeting Salmonella typhimurium (S. typhimurium) A1-R [49]
decoyed quiescent cancer cells in G0/G1 phase cultured in monolayer culture, as tumor spheres
in three-dimensional culture, and tumors in vivo, to begin cycling (Figure 9) [50]. S. typhimurium
A1-R, combined with chemotherapy, inhibited tumor growth compared with S. typhimurium A1-R
monotherapy or chemotherapy alone [50]. FUCCI imaging demonstrated that the decoyed tumor
comprised mostly cancer cells in S/G2M phases, which became sensitive to chemotherapy. The cell-cycle
decoy ability of S. typhimurium A1-R, developed with FUCCI imaging, can lead to a new paradigm of
















methioninase  (rMETase). The  cell‐cycle  trap of  cancer  cells by methionine  restriction was  clearly 
shown by FUCCI  imaging  [51]. The  tumors decoyed by S.  typhimurium and  trapped by  rMETase 
became significantly sensitive to conventional cytotoxic agents [52] (Figure 10). This novel treatment 
strategy has been termed decoy, trap, and kill chemotherapy. 
Figure 9. Cell-cycle decoy of tumor-targeting adenovirus and tumor-targeting Salmonella typhimurium
A1-R, observed with FUCCI imaging. (A) Representative images of the decoy of quiescent cancer
cells in vitro, before and after decoy. Tumor-targeting adenovirus and tumor targeting S. typhimurium
A1-R decoy quiescent cancer cells in tumor spheres from G1 into early-S and late-S/G2 phases (right).
(B) Representative images of decoy of quiescent cancer cells in vivo. Tumor-targeting adenovirus and
S. typhimurium decoy quiescent cancer cells in tumors in vivo into early-S and late-S/G2 phases [22].
Scale bar; 500µm.
6.4. Decoy, Trap, and Kill Cancer Therapy Developed with FUCCI Imaging
FUCCI imaging showed that a tumor-targeting adenovirus decoyed and trapped both quiescent
CSCs and quiescent established tumors from G1 phase to early-S phase, as mentioned above. The CSCs
in early-S phase, decoyed and trapped by the adenovirus, became sensitive to chemotherapy [45]
(Figure 9). S. typhimurium A1-R also decoyed quiescent cancer cells in solid tumors to cycle. After the
decoy, the cancer cells were trapped in S/G2 under methionine restriction effected by recombinant
methioninase (rMETase). The cell-cycle trap of cancer cells by methionine restriction was clearly shown
by FUCCI imaging [51]. The tumors decoyed by S. typhimurium and trapped by rMETase became
significantly sensitive to conventional cytotoxic agents [52] (Figure 10). This novel treatment strategy
has been termed decoy, trap, and kill chemotherapy.
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Figure 10. Decoy, trap, and kill che otherapy ith FUCCI imaging. FUCCI-expressing MKN45
stomach cancer cells (5 × 106 cells/ ouse) were injected subcutaneously into the left flank of nude
mouse. When the tumors reached approximately 8 mm in diameter (tumor volume, 300 mm3),
mice were administered iv S. typhimurium A1-R alone or with cisplatinum (CDDP; 5 mg/kg ip) for 5
cycles every 7 days, in combination with S. typhimurium A1-R and CDDP or in combination with S.
typhimurium A1-R, recombinant methioninase (rMETase; dose ip 200 u/day 3 days/cycle), and CDDP
(5 mg/kg, ip). (A) Treatment schedule. (B) Macroscopic photographs of FUCCI-expressing MKN45
subcutaneous tumors, untreated control: S. typhimurium A1-R-treated, CDDP-treated, or treated
with the combination of S. typhimurium A1-R and CDDP or the combination of S. typhimurium A1-R,
rMETase, and CDDP. (C) Waterfall plot indicating fold change in tumor volume with each treatment.
(D) Representative images of cross-sections of FUCCI-expressing MKN45 subcutaneous tumors,
untreated control: S. typhimurium A1-R-treated, CDDP-treated, or treated with the combination of
S. typhimurium A1-R and CDDP or the combination of S. typhimurium A1-R, rMETase, and CDDP [45].
iv = intravenous; ip = intraperitoneal. Scale bar; 500 µm.
6.5. FUCCI Imaging Demonstrates that Invading Cancer Cells Are Quiescent
FUCCI imaging showed that as cancer cells began to invade, they become quiescent in G0/G1,
expressing FUCCI-red [24]. FUCCI imaging showed that as cancer cells cultured on collagen began
to invade, they also become quiescent in G0/G1, expressing FUCCI-red [53]. Miyashita et al. [54]
showed that the leading edge of invading cells expressed FUCCI-red cancer cells, indicating they were
in G1 phase. These results further show the danger of quiescent cancer cells and the importance of
targeting them.
7. FUCCI Imaging to Evaluate Cell-Cycle-Specific Targeted Drugs
CDK4 and CDK6 play a role in malignant progression [55–62] (Figure 1). FUCCI imaging
demonstrated that the response of FUCCI-expressing HeLa cells to a Cdk4 inhibitor depended on
the cell-cycle phase. Exposure to a Cdk4 inhibitor in early G1, G1/S, or S/G2 phases resulted in G1
arrest. I contrast, exposure to a Cdk4 hibitor in late-G1 p ase esulted the endo eplication of
the cellular DNA in he G1 phase (17). These results indicate that a CDK inhibitor [63–71] induces
G1 arrest. WEE 1 kinase is essential to bypass the G2 checkpoint [72]. WEE1 nhibitors are known to
induce abortive mitosis (endomitosis) since c ncer cells have polypoid nuclei aft r WEE in ibition [72].
Nojima et al. [73] demo strated using FUCCI imaging that mitosis of cancer cells was extended
when the WEE1 inhibitor was applied, and surviving cells were in G1 and expressed FUCCI-red with
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endomitosis. The present review demonstrates that FUCCI can be a useful tool to evaluate and discover
cell-cycle-targeting drugs [74–76] and improve the efficacy of currently-used cell-cycle-targeting drugs.
8. Comparison of FUCCI and Other Cell-Cycle Indicators
There are other methods to monitor the cell cycle. Many types of functional nuclear proteins,
such as histone H2B [77], nuclear localization signal (NLS) [78,79], and proliferating-cell nuclear
antigen (PNCA) [80,81], have been used to monitor specific cell-cycle phases with fluorescent proteins.
Cancer cells transfected with the histone H2B gene fused to the gene-encoding GFP have been used to
monitor mitotic cells in real-time [82]. Dual-fluorescence-colored cancer cells with histone H2B-GFP
and cytoplasm-RFP have also been used to monitor mitosis and nuclear–cytoplasmic interaction in
real-time [83–87]. However, this system only distinguishes mitotic and nonmitotic cells. Recently,
Sparks et al. [88] demonstrated doxorubicin-induced chromatin-changes in-vivo using histone-GFP
and a fluorescence lifetime imaging microscope (FLIM) [89]. This system is an improvement over
the dual-color fluorescent cells and gives more information about mitosis but cannot indicate all cell
cycle phases as FUCCI can [89]. Fusing NLS to fluorescent proteins enabled visualization of cell-cycle
transition from G1 phase to S phase in real-time [78,79]. PCNA linked to fluorescent proteins enabled
visualization of cell-cycle transition from S to G2 phase in real-time [89,90]. However, these makers
cannot track the cell-cycle dynamics of all phases, as modern FUCCI can. Foster resonance energy
transfer (FRET)-image sensors have been used with CDKs-CFP and YFP to monitor cell cycle transition,
but cannot visualize all cell-cycle phases, as modern FUCCI can [91–94]. FUCCI is the most useful tool
to monitor all phases of cell-cycle dynamics in real time [95,96].
9. Conclusions
The resistance of quiescent cancer cells to conventional therapy is currently a recalcitrant clinical
problem. FUCCI imaging demonstrated that most currently-used cytotoxic cancer chemotherapeutic
agents are effective only on cycling cancer cells and have little effect on quiescent/dormant cancer cells
that comprise the majority of the cells within many, if not most, established tumors. FUCCI imaging
can be used to discover drugs that target quiescent cancer cells, a mainly unsolved problem in oncology.
FUCCI imaging in real-time has demonstrated that the cell-cycle position of each cancer cell in
a solid tumor is a major determinant of whether it can respond to cytotoxic chemotherapy. A very
high proportion of G0/G1 quiescent cells in solid tumors makes the tumor resistant to cytotoxic
chemotherapy. FUCCI imaging has demonstrated that the spatial location of cancer cells within a tumor
has a major impact on their cell-cycle behavior. FUCCI imaging can be used to design new cell-cycle
targeted chemotherapy, including using cell-cycle decoy agents to overcome this recalcitrant problem
of chemotherapy resistance of quiescent cells in tumors (Figure 11). Modern FUCCI imaging has critical
advantages over all other current cell-cycle analyses in that it can image and distinguish all phases
of the cell cycle in real-time. FUCCI can be a powerful tool for the discovery of paradigm-changing
cancer therapy in the clinic, such as decoy, trap, and kill therapy, which can have applications in the
near future.
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Figure 11. FUCCI image-guided cell-cycle targeted therapy. (A) FUCCI imaging of solid tumors at
different stages: a nascent tumor comprising mostly cycling cancer cells, an established tumor consisting
of mostly quiescent cancer cells, and some cycling cancer cells. A dormant tumor consisting of mostly
quiescent cancer cells. (B) FUCCI imaging of chemotherapy of an established tumor. (C) FUCCI-guided
cell-cycle-specific targeting with current inhibitors. (D) Cell-cycle decoy, trap, and kill chemotherapy.
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